Traumatic brain injury is one of the most-studied off-label uses of HBOT. It is also one of the most contested. After two decades of trials, the picture is mixed and the FDA has not added TBI to its 13 cleared uses.
This guide walks through what the research actually shows. We cover the major military trials, the recent civilian RCTs, the methodology fights, and what current data does and does not support.
We will also cover what the VA, the DoD, and major medical centers say. This is a "what the evidence shows" review, not a treatment endorsement.
Why TBI got studied at all
TBI is a huge clinical problem. The CDC TBI Surveillance 2024 reports roughly 2.8 million US TBI cases per year, with combat-related cases driving military interest.
Standard TBI care is mostly supportive. There is no FDA-approved drug or device that reverses post-TBI cognitive and emotional symptoms. That gap created strong demand for any therapy with a plausible mechanism.
HBOT had two reasons to attract study. First, hyperoxia might rescue oxygen-starved cells around the injury core. Second, animal models showed reduced inflammation and possible neuron protection at 1.5 to 2.4 ATA.
The major military trials
The Department of Defense funded several large HBOT-for-TBI trials between 2008 and 2017. Three are widely cited.
The HOPPS trial (Miller et al., JAMA Internal Medicine 2015) randomized 72 active-duty service members. It used 1.5 ATA HBOT vs sham. The result: both arms improved, with no significant HBOT-over-sham difference.
The BIMA trial (Weaver et al., Undersea Hyperb Med 2018) tested 1.5 ATA HBOT vs 1.2 ATA sham in 71 service members. The result: small symptom gains in the HBOT arm, but the sham arm also improved substantially.
The Cifu trial (Cifu et al., Neurorehabilitation 2014) used 2.0 ATA vs sham in 50 service members. Again, modest gains in both arms.
The common pattern: TBI patients improve on multiple measures across both HBOT and sham arms. The sham response is unusually large, which makes the HBOT signal hard to read.
Why the placebo response is so big
A central methodology issue. TBI symptoms — headache, brain fog, anxiety, sleep problems — overlap heavily with conditions that respond strongly to placebo, expectation, and structured care.
A patient who enrolls in an HBOT trial gets weekly contact with a study team, regular cognitive testing, structured daily activity, and a sense of being part of a treatment effort. All of those raise the chance of improvement on subjective measures.
The sham control adds further complication. Sham HBOT typically uses 1.1 to 1.3 ATA pressures. Some researchers argue that even 1.3 ATA is therapeutic at some level — meaning the "sham" arm may not be a true placebo.
This is a real methodology fight that has split the HBOT-for-TBI literature. We covered the analogous fight over the long COVID Shamir RCT in our Shamir analysis.
The civilian RCTs
A handful of civilian TBI trials run outside the military system. They are smaller but use similar protocols.
The Boussi-Gross trial (Boussi-Gross et al., PLOS ONE 2013) tested 60 sessions of 1.5 ATA HBOT in 56 post-TBI patients. The HBOT arm showed gains in cognitive testing and quality of life. The trial had no sham control, which limits its strength.
The Hadanny trial (Hadanny et al., Scientific Reports 2020) extended the work with a larger crossover design. It reported symptom and brain imaging gains.
Both Israeli civilian trials run at the Sagol Center used 60-session protocols at 1.5 to 2.0 ATA. The methodology — same site, same team, no independent replication — is part of the methodology critique.
What the VA and DoD currently say
The Department of Veterans Affairs does not cover HBOT for TBI. The VA HBOT policy 2023 lists HBOT for the 13 FDA-cleared indications only.
The DoD has funded large research efforts but has not added HBOT-for-TBI to standard care. Active-duty service members can access HBOT only through research protocols, not as a routine treatment.
The position is consistent with the FDA's: the data is interesting but not yet enough to support broad clinical use. This is one of the regulatory gaps we cover in our institutional silence analysis.
What the major medical centers say
Major US academic medical centers are largely silent on HBOT-for-TBI. Cleveland Clinic, Mayo Clinic, Johns Hopkins, and similar centers either do not mention the use or note it is not yet supported.
The American Academy of Neurology 2021 guidelines on chronic TBI do not list HBOT as a recommended treatment. The American Heart Association, American College of Physicians, and similar bodies are also silent.
A handful of academic centers offer HBOT-for-TBI in research contexts. Most off-label HBOT-for-TBI in the US runs at wellness clinics, not hospitals.
The off-label HBOT-for-TBI market
A practical reality. Despite the mixed data, demand for HBOT-for-TBI is substantial. Veterans, athletes with concussion history, and TBI survivors drive demand.
Wellness clinics fill the gap. Most offer 1.3 to 1.5 ATA protocols at 20 to 60 sessions, with costs ranging from $4,000 to $20,000 per course. Insurance does not pay.
The Boca Raton anti-aging brand and a handful of similar premium operators offer the 60-session, $50,000 protocol marketed for cognitive function. The data behind these protocols is the Sagol Center Israeli research, not US RCTs.
For more context on the anti-aging brand's protocol, see our evidence-vs-marketing review.
What patients should know before pursuing HBOT-for-TBI
A few things to consider. The data is mixed, with most rigorous trials showing little or no advantage of HBOT over sham. Smaller trials and uncontrolled studies show larger gains.
The placebo response in TBI symptom improvement is large. Many patients improve on HBOT, but many also improve on sham. The improvement is real; the cause is contested.
Costs are substantial and not covered by insurance. A 40-session course at a wellness clinic runs $4,000 to $20,000. A 60-session premium protocol runs $30,000 to $50,000.
Severe adverse events are rare but real. The FDA HCP letter 2014 covers fire risk and oxygen-related harm.
A reasonable patient framework
If you are considering HBOT-for-TBI, three steps. First, set a session-count and dollar budget before signing on. A 20-session trial at 1.5 ATA is a reasonable starting point.
Second, define what improvement would look like. Use validated symptom scales (Rivermead, Beck Depression Inventory, MoCA) so you have an objective check at session 20.
Third, plan a re-evaluation point. If you see no measurable change by session 20, the math for continuing weakens. Sunk-cost bias is a real risk in HBOT.
Bottom line
HBOT-for-TBI is studied, plausible, and off-label. The largest US military trials found no significant advantage over sham. Smaller civilian trials suggest a real but modest effect.
The FDA has not added TBI to its 13 cleared uses. The VA does not cover it. The DoD does not use it as standard care.
If you pursue it, treat it as experimental. Set a budget and a measurement plan, then re-evaluate at 20 sessions. Do not assume more sessions equals better outcome without data.
Related Reading
- HBOT for long COVID: Shamir RCT analysis
- HBOT for athletic recovery: endorsements vs evidence
- HBOT for ADHD: what the evidence shows
- What major institutions are not saying about HBOT
- FDA-cleared HBOT chambers: complete list
Frequently asked questions
Does Medicare or the VA cover HBOT for TBI?
No. Both follow the FDA list of 13 cleared uses. TBI is not on that list. Off-label HBOT-for-TBI is self-pay only.
Did the military trials show HBOT works for TBI?
The largest military trials (HOPPS, BIMA, Cifu) showed that both HBOT and sham arms improved, with no significant advantage of HBOT over sham on the primary outcomes.
Why is the placebo response so large in TBI HBOT trials?
TBI symptoms overlap heavily with conditions that respond strongly to placebo, expectation, and structured care. Trial enrollment itself raises the chance of improvement on subjective measures.
How much does off-label HBOT-for-TBI cost?
A 40-session wellness clinic course runs $4,000 to $20,000. A 60-session premium anti-aging protocol runs $30,000 to $50,000. Insurance does not pay.
Is there any HBOT-for-TBI use that major centers do endorse?
No major US academic medical center endorses HBOT-for-TBI as standard care. A handful offer it in research contexts. Most off-label HBOT-for-TBI runs at wellness clinics, not hospitals.
Medical disclaimer: This article is informational and does not constitute medical advice. HBOT carries real risks including ear injury, oxygen-related harm, and chamber fire. The FDA has cleared HBOT for 13 specific uses; TBI is not on that list. Discuss any HBOT plan with a doctor trained in hyperbaric medicine before starting.
-- The HBOT Finder Team